PBRM1 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Remarkably, of the 24 patients with tRCC treated with the ICI analyzed, two patients had long lasting responses to ICI, extending beyond six months, and both of these patients harbored a PBRM1 mutation [27,40].